A recent study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ) by Prof Dominic J. Withers, Dr. Selman C and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy: ANGPTL1 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 25/January/2015, 11.24 pm.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Lifespan extension therapy: ANGPTL1 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 25/January/2015, 11.24 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Significance: This study suggests, for the first time, that ANGPTL1, by regulating the expression of its target gene, it may inhibit the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase). Thereby, it may promote (1) resistance to bone, immune, and motor dysfunction; and (2) and insulin sensitivity. Thus, pharmacological formulations encompassing “ANGPTL1 activators” may be used to extend an individual’s life span.
Undisclosed information: How ANGPTL1 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase)
